Form 4: Mirum CEO Exercises Options, Sells Shares

Mirum Pharmaceuticals CEO Christopher Peetz exercised stock options and sold 40,000 shares for a significant gain under a pre-arranged trading plan.

Summary

• Christopher Peetz, CEO and Director of Mirum Pharmaceuticals, Inc. (MIRM), engaged in a pre-scheduled transaction.
• On August 11, 2025, Peetz acquired 40,000 shares of common stock by exercising employee stock options at a price of $2.936 per share.
• Concurrently, Peetz sold 40,000 shares of common stock at a price of $62 per share.
• The transactions were executed pursuant to a Rule 10b5-1 Plan adopted on November 22, 2024.
• Following these transactions, Peetz's direct beneficial ownership of common stock decreased to 138,641 shares.
• Peetz also indirectly beneficially owns 208,570 shares through The Peetz Family Trust.
• The exercised stock option was fully vested and has an expiration date of March 11, 2029.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While insider selling can sometimes be viewed negatively, the significant profit realized by the CEO and the execution under a Rule 10b5-1 plan mitigate concerns, suggesting a planned liquidity event rather than a lack of confidence in the company.

Positives

• The sale price of $62 per share represents a substantial gain over the exercise price of $2.936 per share, indicating significant value creation for the option holder.
• The transaction was conducted under a Rule 10b5-1 plan, which suggests a pre-planned, non-discretionary sale, often viewed positively as it mitigates concerns about insider trading based on non-public information.

Negatives

• The sale of shares by a CEO, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct stake in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report for a pharmaceutical company executive. It does not provide insights into broader industry trends or competitive dynamics, focusing solely on personal stock transactions.

Related Party Transactions

• The reported transactions involve the CEO of Mirum Pharmaceuticals, Christopher Peetz, exercising stock options and selling shares of the company, which are inherent related party transactions as they involve an executive and the company's securities.

Stakeholder Impact

• Shareholders: The sale by the CEO could be interpreted in various ways; some might see it as a negative signal, while others might view it as a routine liquidity event, especially given the 10b5-1 plan. The significant profit realized by the CEO highlights the potential value of the company's stock options.
• Employees: No direct impact on employees is indicated, but executive compensation practices are often of interest.
• Creditors, Customers, Suppliers: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

The filing details a pre-scheduled insider transaction (option exercise and sale) by the CEO, which is a routine event for executives managing their compensation and liquidity. While the sale reduces the CEO's direct stake, the execution under a 10b5-1 plan suggests it's not based on new, negative information. The significant profit realized by the CEO from the option exercise is a positive for the individual but does not inherently change the fundamental outlook for the company. Therefore, this specific filing alone does not warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further fundamental analysis of Mirum Pharmaceuticals' business performance and prospects.

Keywords

Mirum Pharmaceuticals, MIRM, Christopher Peetz, CEO, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Executive Compensation